Podcasts about molecular

Ross Halls and Stuart Watson are back to discuss all things Ipswich Town ahead of this weekend's home clash with Derby County. The boys start with some sexy stuff, with the shocking news that Norwich City midfielder Marcelino Nunez is set to join Town.  There's a chat around another potential signing in Darnell Furlong from West Brom and the state of play at Town ahead of transfer deadline day.  Then it's onto looking ahead to the Rams visit to Portman Road and much more. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

In this episode of the Health Fix Podcast, Dr. Jannine Krause sits down with Nagina Abdullah, weight-loss coach for midlife women and founder of the top-rated website MasalaBody.com. Nagina shares her personal journey of losing 40 pounds after years of struggling with diets that didn't work. She opens up about the power of understanding blood sugar balance, how spices like cinnamon can help reduce cravings and improve metabolism, and why focusing on adding nutritious foods works better than restriction. Nagina also introduces her slim down programs and a free metabolism-boosting workshop designed specifically for women in midlife who feel stuck and frustrated with traditional diets.

Dr. Alex Meves, distinguished dermatologist at the Mayo Clinic and a spokesperson for SkylineDx, discusses the challenges in diagnosing and treating melanoma and how a new molecular test called Merlin can help improve risk stratification and treatment decisions for patients with early-stage melanoma. Diagnosis and treatment have traditionally used tumor thickness as a primary risk factor. This molecular test measures the expression of genes in the tumor biopsy and can help determine the extent of surgery needed and whether additional therapies may be beneficial. Alex explains, "My department, when I started to work here at Mayo, wanted me to do some translational research, and I had just come back from a postdoc in Germany, at the Max Planck Institute, and I was tasked to get some research going. And so I focused on melanoma because I thought at the time there wasn't a lot of molecular research going on in melanoma that could be translated to patients. And so we started to develop biomarkers, sort of molecular tests that we could apply to tissue, and then help patients with." "Yes, so the problem that our research is focused on is what to do once you're diagnosed with a melanoma. What you want to do is to match the right therapy to the right patient. That's the goal. There are lots of melanomas that might not be very aggressive, and you don't have to do a lot of treatment. And then there's some melanoma that's very aggressive, and you want to do lots of treatment, but it's not always obvious which melanoma is low risk and which melanoma is high risk. And so this idea of risk stratification at diagnosis becomes very important to match therapy to patients." #skincancer #melanoma #SkylineDx #PersonalizedMedicine #PrecisionDiagnostics skylinedx.com Download the transcript here

Dr. Alex Meves, distinguished dermatologist at the Mayo Clinic and a spokesperson for SkylineDx, discusses the challenges in diagnosing and treating melanoma and how a new molecular test called Merlin can help improve risk stratification and treatment decisions for patients with early-stage melanoma. Diagnosis and treatment have traditionally used tumor thickness as a primary risk factor. This molecular test measures the expression of genes in the tumor biopsy and can help determine the extent of surgery needed and whether additional therapies may be beneficial. Alex explains, "My department, when I started to work here at Mayo, wanted me to do some translational research, and I had just come back from a postdoc in Germany, at the Max Planck Institute, and I was tasked to get some research going. And so I focused on melanoma because I thought at the time there wasn't a lot of molecular research going on in melanoma that could be translated to patients. And so we started to develop biomarkers, sort of molecular tests that we could apply to tissue, and then help patients with." "Yes, so the problem that our research is focused on is what to do once you're diagnosed with a melanoma. What you want to do is to match the right therapy to the right patient. That's the goal. There are lots of melanomas that might not be very aggressive, and you don't have to do a lot of treatment. And then there's some melanoma that's very aggressive, and you want to do lots of treatment, but it's not always obvious which melanoma is low risk and which melanoma is high risk. And so this idea of risk stratification at diagnosis becomes very important to match therapy to patients." #skincancer #melanoma #SkylineDx #PersonalizedMedicine #PrecisionDiagnostics skylinedx.com Listen to the podcast here

Today, I'm joined by Naveen Jain, founder of Viome.  Analyzing 100M biomarkers, Viome delivers hyper-personalized nutrition and supplement recommendations based on individual molecular biology. In this episode, we discuss the power of personalized medicine. We also cover: Why DNA testing falls short Molecular insights into chronic disease Enabling N-of-1 nutrition and supplement stacks Subscribe to the podcast → insider.fitt.co/podcastSubscribe to our newsletter → insider.fitt.co/subscribeFollow us on LinkedIn → linkedin.com/company/fittinsider Viome's Website: https://www.viome.com/ Viome's Publications: https://www.viome.com/publications - The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart workout solutions for fitness and health facilities. Fitt Talent: https://talent.fitt.co/ Consulting: https://consulting.fitt.co/ Investments: https://capital.fitt.co/ Chapters: (00:00) Introduction (02:05) Entrepreneurial Framework (08:15) Healthcare System Incentives (11:12) Viome's Mission & Technology Approach (18:50) Los Alamos Partnership & RNA Analysis (22:41) Full Body Intelligence Test & Personalized Recommendations (23:34) Retesting Frequency & Dynamic Health Changes (24:20) Healthcare System Barriers (31:02) Scientific Differentiation (35:24) Early Disease Detection (39:42) Scaling to Reach Billions (45:15) Conclusion

Alex Jones, Ross Halls and Mark Heath are back to discuss all things Ipswich Town after their deflating defeat 1-0 defeat at Preston. The boys reflect briefly on the Preston loss, before moving on to tackle some recurring themes around Town. We hear from Kieran McKenna about building a new team and share our thoughts on that, plus Town's lack of goals and set piece struggles. We also debate Conor Chaplin's role, and ponder if it's time to unleash Jack Clarke back on the left with the brief he had at Sunderland. We finish by talking about the last few days of the transfer window, what Town need - and our gut feelings on the season ahead. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Alex Jones, Ross Halls and Mark Heath are back to discuss all things Ipswich Town ahead of this weekend's trip to Preston. The boys start with some sexy stuff, which rapidly gets sexier as Kasey McAteer signs live on the pod. There's a chat around another looming sad departure too, with Luke Woolfenden heading for the exit door and a link to a potential Uruguayan replacement. Then it's onto a chat around yesterday's pressers and KMac's very honest insight on this transfer window, before we finish by trying to predict the starting XI at Preston and the result. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Mehek Mohan is a Stanford Graduate School of Business student and the co-founder of Kahani, a personalized recovery platform for individuals navigating eating disorders. Prior to Stanford, Mehek led AI and automation initiatives at Genentech within the Early Clinical Development team. She earned her undergraduate degree in Molecular and Cell Biology from UC Berkeley and has experience in early-stage venture capital. Mehek is passionate about making mental health care tools more accessible by leveraging cutting-edge advances in technology. We will take a deep dive into this recovery platform to learn and understand how technology has the potential to improve outcomes. This platform is new, an 8-week pilot program was launched in April of this year just as we were recording this podcast.  Kahani is a digital recovery companion designed to help individuals navigating eating disorder recovery by providing structured, evidence-based activities in a game-like format.Think Inside Out meets Duolingo meets Farmville!   Email:  mmehek@stanford.edu  Linkedin:  https://www.linkedin.com/in/mehekmohan/ Our Hosts:   ·         Linda and John(Jack) Mazur founded a nonprofit 501(c)3 organization in 2022 in memory of their daughter, Emilee which provides peer support, social connection, and education for adults with eating disorders and for their family members. For more information or to contact them go to: www.theemileeconnection.com  Linda and John (Jack) Mazur wrote, Emilee: The Story of a Girl and Her Family Hijacked by Anorexia, to honor their daughter's wish, to raise awareness, evoke compassion, and foster change in how eating disorders are viewed and treated. Paperback: and Kindle:https://www.amazon.com/Emilee-Story-Family-Hijacked-Anorexia/dp/170092012X        Audiobook :https://www.amazon.com/Emilee-Story-Family-Hijacked-Anorexia/dp/B08R6LRPDS        Linda and Jack can also be reached through the book website:   https://emileethestoryofagirl.com or at Linda.john.mazur@gmail.com  Ellen Bennett is the director of KMB for Answers, a non-profit charity providing educational and financial support for mental health professionals as well as assistance for families in search of resources. For more information about Ellen Bennett and the foundation founded in memory of her daughter Katlyn, go to: www.Kmbforanswers.com

Ross Halls and Tom Cann are back with our Ipswich Town Women's podcast as they discuss the latest news. The duo chat about pre-season for Joe Sheehan's side and five new signings in Ruby Doe, Bethan Roe, Jenna Dear, Grave Neville and Sophie Baigent. Plus share their thoughts a tough draw in the Subway Women's League Cup, season ticket details and looking ahead to the WSL 2 season.  Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Are typical mouthwash products effective and are they worth recommending to our patients? Are there any products out there that can actually make a significant difference in our fight against perio disease? Our guest, Dr. Steven Milman, will address these questions and more. Dr. Milman received his dental degree from Baylor College of Dentistry in Dallas, Texas. He completed his Periodontal residency at the University of Texas Health Science Center in San Antonio. He was a researcher in periodontal microbiology and was a full time periodontist in his private practice in Round Rock and Austin, Texas for 36 years. Thanks to our episode sponsors: BISCO - https://www.bisco.com/ Solventum - https://www.solventum.com/en-us/home/oral-care/

This episode of the Oil & Gas Measurement Podcast features an interview with Landen Beckham from e9 Treatments. The discussion centers on e9's molecular coating, which is designed to reduce buildup and fouling on oil and gas measurement equipment, and how it can extend the operational life of meters. The conversation covers the benefits of this treatment, with a focus on its application for mag meters, Coriolis meters, and provers. Visit PipelinePodcastNetwork.com for a full episode transcript, as well as detailed show notes with relevant links and insider term definitions.

Alex Jones and Mark Heath are back to discuss Ipswich Town's 1-1 draw with Southampton on the latest KOA podcast. The duo chat about Town's flying start and subsequent drop in intensity, Azor Matusiwa's battle with Adam Armstrong and Jaden Philogene's encouraging display. There's a debate around Sammie Szmodics and the No.10 position too, plus a warm welcome back for Jens Cajuste. Then it's onto not so sexy stuff as Omari and Broady depart, plus we learn a Spanish striker won't be signing - but a €20m Norwegian winger might! Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

In this first episode of our deep-dive series, I'm breaking down the hidden connection between total toxic burden, molecular mimicry, and autoimmune conditions like Hashimoto's thyroiditis. We'll explore: How living with mold toxins, chemicals, heavy metals, and infections keeps your immune system stuck in overdrive Why toxic burden overload can push your body into autoimmune mode — even if your labs were normal for years The science of molecular mimicry and how gluten, viruses, and environmental triggers can “trick” your immune system into attacking your thyroid Why a gluten-free diet is non-negotiable for thyroid autoimmunity — and how even a single exposure can keep the immune attack going for months The role of gut health, nutrient deficiencies, and detox pathways in calming the autoimmune fire This isn't just about managing symptoms — it's about finding and removing the root cause triggers so your body can regain immune tolerance and repair itself. If you've been told “your labs look fine” but you still feel tired, inflamed, or foggy, Part One will help you connect the dots and see why true thyroid healing starts far beyond the thyroid itself.

In this first episode of our deep-dive series, I'm breaking down the hidden connection between total toxic burden, molecular mimicry, and autoimmune conditions like Hashimoto's thyroiditis. We'll explore: How living with mold toxins, chemicals, heavy metals, and infections keeps your immune system stuck in overdrive Why toxic burden overload can push your body into autoimmune mode — even if your labs were normal for years The science of molecular mimicry and how gluten, viruses, and environmental triggers can “trick” your immune system into attacking your thyroid Why a gluten-free diet is non-negotiable for thyroid autoimmunity — and how even a single exposure can keep the immune attack going for months The role of gut health, nutrient deficiencies, and detox pathways in calming the autoimmune fire This isn't just about managing symptoms — it's about finding and removing the root cause triggers so your body can regain immune tolerance and repair itself. If you've been told “your labs look fine” but you still feel tired, inflamed, or foggy, Part One will help you connect the dots and see why true thyroid healing starts far beyond the thyroid itself.

Stuart Watson and Mark Heath return with a midweek KOA pod in the wake of Ipswich Town's grimly predictable cup exit at the hands of Bromley. The boys discuss the game, highlight players who impressed and who didn't, and ponder the future for Ali Al-Hamadi. Then it's on to the latest in the Omari Hutchinson saga, a chat around Nathan Broadhead and reflections on the general mood around the club. We finish with a look ahead to Southampton and discuss what sort of XI we might see on Sunday. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

In this episode, Prof Chris Vorster (Director, Centre for Human Metabolomics, North-West University, South Africa), Sarah Viall (Assistant Professor, Molecular and Medical Genetics, Oregon Health & Science University, USA) and PD Dr. med. Ulrike Mütze (Consultant, Heidelberg University Hospital, Germany) join Silvia Radenkovic and Rodrigo Starosta to explore the evolving landscape of newborn screening. They discuss national and international variations in practice, how to maintain consistency and quality, and the future scope of testing – including opportunities to improve access in resource-limited settings. Authors' opinions are their own and do not represent their institutions. Referenced papers include: Newborn screening in South Africa: the past, present, and plans for the future. Malherbe et al (2024) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. McHugh et al (2024) Five years of newborn screening for Pompe, Mucopolysaccharidosis type I, Gaucher, and Fabry diseases in Oregon. Viall & Held (2025) Long-term outcomes of adolescents and young adults identified by metabolic newborn screening. Mütze et al (2025) Treatment Outcomes for Maple Syrup Urine Disease Detected by Newborn Screening. Mengler et al (2024) Vitamin B12 Deficiency Newborn Screening. Mütze et al (2024) The role of exome sequencing in newborn screening for inborn errors of metabolism. Adhikari et al (2020)

Ross Halls is joined by Stuart Watson and Alex Jones to reflect on Ipswich Town's 1-1 draw at Birmingham City. But first, it's a transfer update, with Jens Cajuste and Chuba Akpom both through the door, while Omari Hutchinson and Nathan Broadhead both face uncertain futures. Then it's onto the Championship curtain-raiser, a fiery 1-1 draw at Birmingham, with Town striking late on to earn a vital point at St. Andrew's. There's also a chat around tomorrow's Carabao Cup clash at Bromley, and we welcome new sponsors Molecular to join the returning Stardust Spirits. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

Schau dir das Video zu dieser Folge an: Keto bei KREBS: Mythos oder Wahrheit? | Die ECHTE Wissenschaft der ketogenen Ernährung gegen KrebsYouTube Kanal gleich abonnieren und keine neue Folge mehr verpassenZusammenfassungIn dieser Episode räumt Julia Tulipan mit den Mythen rund um die ketogene Ernährung bei Krebs auf. Anstatt polarisierender Social-Media-Debatten liefert sie eine wissenschaftlich fundierte Analyse der Studienlage. Du erfährst, dass es nicht darum geht, den Tumor "auszuhungern", sondern um die komplexen Wirkmechanismen von Ketonen: Sie senken Blutzucker und Insulin, reduzieren Entzündungen, modulieren das Immunsystem und können gesunde Zellen schützen, während sie Tumorzellen für Therapien verwundbarer machen. Julia klärt die Fakten zum Warburg-Effekt (nicht widerlegt!) und zur metabolischen Flexibilität von Krebszellen. Sie entkräftet die Behauptung, Ketone würden Tumore füttern, und zeigt stattdessen die antitumorale Wirkung, die in vielen Studien beobachtet wird. Wir beleuchten vielversprechende klinische Studien zu Bauchspeicheldrüsen- und Brustkrebs, die zeigen, wie Keto in Kombination mit Standardtherapien die Krankheitsstabilität und Lebensqualität verbessern kann. Julias Fazit: Keto ist kein Allheilmittel, aber eine wissenschaftlich gut begründete, ergänzende Strategie, die die Wirksamkeit konventioneller Therapien unterstützen und Nebenwirkungen reduzieren kann. Eine professionelle Begleitung ist dabei unerlässlich.Was du in dieser Episode lernst

In this episode of the Epigenetics Podcast, we talked with Erica Korb from the University of Pennsylvania about her work on BRD4 and the histone variant H2BE, which influences synaptic genes and neuronal activity. Dr. Korb discusses the focus of her lab, which centers on epigenetic mechanisms impacting gene regulation in neurons. Her research primarily examines histone biology and its connection to neurodevelopmental disorders, including autism spectrum disorder and intellectual disabilities. Dr. Korb expounds on the collaborative environment at UPenn's Epigenetics Institute, emphasizing how the rich diversity of research topics fosters innovative ideas and projects within the community. Reflecting on her earlier work from her postdoctoral studies, Dr. Korb discusses her first significant findings regarding the protein BRD4. This work demonstrated BRD4's role in mediating transcriptional regulation crucial for learning and memory processes. She explains how disrupting this protein's function in neurons hindered critical gene activations required for memory formation in mice. This foundational understanding opened avenues for exploring the broader implications of chromatin regulation in various neurodevelopmental conditions. Transitioning into her current research endeavors, Dr. Korb reveals how she aims to expand her focus beyond Fragile X syndrome. With her lab now investigating multiple chromatin regulators implicated in various forms of autism spectrum disorders, she describes a recent project where RNA sequencing exposed substantial overlaps in gene expression changes associated with five distinct chromatin modifiers, each contributing uniquely to neuronal function while collectively demonstrating sensitivity to chromatin disruptions. A significant portion of the discussion centers around Dr. Korb's unexpected exploration into how COVID-19 intersects with chromatin biology through a phenomenon known as histone mimicry. Leveraging bioinformatic tools during the pandemic, her lab discovered that certain viral proteins mimic histone sequences, which may lead to altered transcriptional outputs in host cells. This coincidental finding illustrates both the creative adaptability needed in scientific research and the importance of collaborative efforts across disciplines to uncover new insights. The conversation also delves into Dr. Korb's recent work regarding the histone variant H2BE, initiated by one of her graduate students. She explains how prior research only recognized H2BE's expression in the olfactory system, yet her lab has demonstrated its significant role in regulating synaptic genes and memory formation throughout broader neuronal contexts. Notably, they identified a single amino acid change that influences H2BE's function in chromatin accessibility and gene transcription, emphasizing its potential evolutionary conservation across species. In terms of H2BE's role, Dr. Korb elucidates that its activity is integral in response to extracellular stimuli, particularly within the context of neuronal activation. Intriguingly, they found that H2BE expression decreases in reaction to long-term neuronal stimulation, suggesting a complex mechanism of homeostatic plasticity crucial for regulating neuronal activity levels. This research not only advances understanding of chromatin dynamics but also holds implications for neuronal health and disease mechanisms.   References Feierman, E. R., Louzon, S., Prescott, N. A., Biaco, T., Gao, Q., Qiu, Q., Choi, K., Palozola, K. C., Voss, A. J., Mehta, S. D., Quaye, C. N., Lynch, K. T., Fuccillo, M. V., Wu, H., David, Y., & Korb, E. (2024). Histone variant H2BE enhances chromatin accessibility in neurons to promote synaptic gene expression and long-term memory. Molecular cell, 84(15), 2822–2837.e11. https://doi.org/10.1016/j.molcel.2024.06.025 Korb, E., Herre, M., Zucker-Scharff, I., Gresack, J., Allis, C. D., & Darnell, R. B. (2017). Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition. Cell, 170(6), 1209–1223.e20. https://doi.org/10.1016/j.cell.2017.07.033 Kee, J., Thudium, S., Renner, D. M., Glastad, K., Palozola, K., Zhang, Z., Li, Y., Lan, Y., Cesare, J., Poleshko, A., Kiseleva, A. A., Truitt, R., Cardenas-Diaz, F. L., Zhang, X., Xie, X., Kotton, D. N., Alysandratos, K. D., Epstein, J. A., Shi, P. Y., Yang, W., … Korb, E. (2022). SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry. Nature, 610(7931), 381–388. https://doi.org/10.1038/s41586-022-05282-z Feierman, E. R., Paranjapye, A., Su, S., Qiu, Q., Wu, H., & Korb, E. (2024). Histone variant H2BE controls activity-dependent gene expression and homeostatic scaling. bioRxiv : the preprint server for biology, 2024.11.01.620920. https://doi.org/10.1101/2024.11.01.620920   Related Episodes Neuroepigenetic Mechanisms and Primate Epigenome Evolution (Boyan Bonev) DNA Methylation Alterations in Neurodegenerative Diseases (Paula Desplats) The Role of Histone Dopaminylation and Serotinylation in Neuronal Plasticity (Ian Maze)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Stuart Watson, Alex Jones, Mark Heath and Ross Halls are back with one of the biggest KOA pods of any year - our season preview! First, the boys chat about the latest transfer news, with Chuba Akpom and Jens Cajuste on the way in and Omari Hutchinson, Nathan Broadhead and Leif Davis all being linked with moves away. Then it's on to the main event - our big season preview. We predict who's going to be Town's leading scorer, MVP, surprise package and more - plus the big one, where Town will finish. There's still time for a look ahead to the season opener at Birmingham and our first predictions of the season, plus we welcome a new sponsor on board. Kings of Anglia is sponsored by Stardust Spirits. Get 20% OFF with promo code KOA at https://www.stardustspirits.co.uk/ Introducing our new sponsors at Molecular! Get 10% OFF with promo code KOA10 at https://www.molecular-uk.com/ Subscribe on our website to watch the video version of the podcast - https://www.eadt.co.uk/subscribe/ You can shop the KOA range here - (kings-of-anglia.myspreadshop.co.uk) 

On this episode, Erik Wallenberg and Joshua Frank talk to Nafis Hasan about his new book, Metastasis: The Rise of the Cancer-Industrial Complex and the Horizons of Care. Nafis Hasan received his PhD in Cell, Molecular and Developmental Biology from Tufts University in 2019. He is currently an Associate Faculty at the Brooklyn Institute for More The post The Cancer-Industrial Complex w/ Nafis Hasan appeared first on CounterPunch.org.

Esta semana hablaremos de sexo a lo bruto, sin pelos en la lengua o, incluso, con pelos en la lengua. Vamos a hablar de sexo en plan salvaje (a estas horas se puede). RICARDO MOURE es Biólogo Molecular y Doctor en Biotecnología Biomédica y ha escrito SEXO SALVAJE. EL KAMASUTRA DE LA NATURALEZA. Vaya, cosas de animalitos: hormigas, monos, ornitorrincos... Con las ganas os quedáis, a no ser que seáis de zoofilia... Hablando de esto, el cuento de Pep Bruno se titula EL REY PAJARINO AMOR; un cuento que ha recogido en Panamá, un sitio donde hay un canal y hacen sombreros. Javier Armentia nos habla de la chorrada de los EMOJIS esos del móvil; tú me dirás que hay de ciencia en esto (pues lo mismo digo yo). Los Sergios se han quedado en uno, porque el otro (Martín) ya se ha evaporado; menos mal que nos queda el bueno, el Fernández, y nos va a hacer una VICHYSSOISE, que cae muy bien en estos caloresEscuchar audio

The postglacial history of the Saimaa ringed seal Science Sessions are brief conversations with cutting-edge researchers, National Academy members, and policymakers as they discuss topics relevant to today's scientific community. Learn the behind-the-scenes story of work published in the Proceedings of the National Academy of Sciences (PNAS), plus a broad range of scientific news about discoveries that affect the world around us. In this episode, Jaakko Pohjoismäki, Jukka Jernvall, and Ari Löytynoja discuss the evolutionary history of the Saimaa ringed seal. In this episode, we cover: •[00:00] Introduction •[01:06] Molecular biologist Jaakko Pohjoismäki introduces Lake Saimaa and the Saimaa ringed seal. •[02:30] Zoologist Jukka Jernvall talks about the characteristics of species isolated by glaciation. •[03:27] Evolutionary biologist and bioinformatician Ari Löytynoja explains the genetic and demographic methods of the study. •[04:11] Löytynoja and Jernvall explain why the results were surprising and where the study turned next. •[06:20] Pohjoismäki and Löytynoja describe the study's implications for biodiversity in postglacial habitats. •[07:50] Jernvall and Löytynoja talk about the study's caveats and limitations. •[10:14] Conclusion. About Our Guests: Jaakko Pohjoismäki Professor University of Eastern Finland Jukka Jernvall Professor University of Helsinki Ari Löytynoja University Lecturer University of Helsinki View related content here: https://www.pnas.org/doi/abs/10.1073/pnas.2503368122 Follow us on Spotify, Apple Podcasts, or wherever you get your podcasts for more captivating discussions on scientific breakthroughs! Visit Science Sessions on PNAS.org: https://www.pnas.org/about/science-sessions-podcast  Follow PNAS: Twitter/X Facebook LinkedIn YouTube Sign up for the PNAS Highlights newsletter

En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=3Q4upx_TOPI Cada persona sintoniza con diferentes energías según su frecuencia: guías, ángeles, maestros, animales de poder... Descubre cómo ir más allá de los sentidos, soltar el ruido mental y confiar en tu percepción. Expandir tu intuición te permite conectar con tus Guías, recibir claridad y direccionar tu camino. Patricia Poustkova Doctora en Genética Molecular, formada con maestros internacionales en percepción, canalización y mediumnidad. Hoy es Médium, Terapeuta Energética y Mentora para desarrollar tu percepción y conectar con el mundo sutil. https://www.almahealing.net / _almahealing Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------INFORMACIÓN SOBRE MINDALIA----------DPM Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.

Send us a textThe future of cancer treatment is on the horizon, but can we afford it, regulate it, and deliver it at scale?In this episode of the HealthBiz Podcast, Dr. Jason Bock, Co-founder and CEO of CTMC, discusses the progress of CAR T cell therapy, the challenges of scaling manufacturing for personalized treatments, and how new payment and policy models can support broader access. He shares inspiring patient success stories, insights into the future of solid tumor therapies, and CTMC's mission to bring advanced therapies to more patients, faster.

Hosts Roz and Alberto are joined by new Editorial Fellow Dr. Sofia Bin to discuss the key articles of the August issue of the American Journal of Transplantation. Dr. Sofia Bin is an assistant professor of medical and surgical sciences at the University of Bologna.   [02:46] Gut microbiome alterations precede graft rejection in kidney transplantation patients [10:31] Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study Editorial: Graft biopsy reimagined: Integrating morphology and molecular maps [22:20] Does a changing donor pool explain the recent rise in the United States kidney nonuse rate? [32:45] A scintigraphic look at the dead donor rule in donation after the circulatory determination of death with the use of normothermic regional perfusion: A single-center interventional trial Editorial: Normothermic regional perfusion in donation after circulatory determination of death—Confirming the absence of brain reperfusion [37:03] Global variation in living donor liver transplantation practices impacts donor and recipient short-term outcomes: initial insights from the International LDLT Registry

Microcosmos Records presents a meditative electronic journey, the album Panta Rhei by Jule Grasz. Jule Grasz (Germany) began composing music in early childhood. In the 1990s, she wrote songs while collaborating with various artists. In 2006, she discovered the world of electronic music production, and since 2008, she has been successfully releasing her chillout music on multiple labels, including Microcosmos Records. Panta Rhei in Ancient Greek means "Everything flows". As Jule herself describes, the album is a musical interpretation of the philosophical principle of perpetual change as the foundation of existence: «Everything comes into being, everything is one, everything flows, everything passes away, in an eternal metamorphosis of being.» The tracks radiate optimism and joy. Artfully textured soundscapes evoke an ever-changing eternity of the cosmos, while hypnotic arpeggios guide listeners through intricate sonic corridors like winding staircases. Press play on Panta Rhei and immerse yourself in the unhurried flow of refined chillout music by Jule Grasz and Microcosmos Records.

Show notes: (0:00) Intro (1:12) Nagina's struggle and breakthrough (5:09) Energy in midlife (6:44) #1 reason women can't lose weight in midlife (11:51) Why food, not workouts, is key to a faster metabolism (15:10) Fat-burning breakfast tips: protein, fiber, and healthy fats (23:12) Swapping hidden sugar bombs for better choices (28:05) Making your smoothies (33:01) Cinnamon, vinegar, and other blood sugar-lowering tricks (42:10) Free gifts and how to connect with Nagina directly (45:48) Outro   Who is Nagina Abdullah?   Nagina Abdullah is a weight loss coach for women in midlife and the founder of the top-rated website MasalaBody.com. She holds a degree in Molecular and Cell Biology from UC Berkeley and earned her MBA from NYU. After personally losing 40 pounds by naturally boosting her metabolism, she began helping other women—especially those over 40—achieve lasting weight loss without extreme dieting or restriction.   Over the past several years, she has coached more than 1,600 women to slim down, reduce belly fat, increase their energy, and regain confidence in their bodies. Nagina's signature approach focuses on adding metabolism-boosting foods, not cutting calories, and her science-backed methods have helped thousands transform their lifestyles for good.   Connect with Nagina: Website: https://masalabody.com/ IG: https://instagram.com/masalabody   DM “sweet” on IG to get the Free Sweet Spice Cheat Sheet   Schedule a Free Midlife Metabolism Discovery Call: https://www.masalabody.com/apply Links and Resources: Peak Performance Life Peak Performance on Facebook Peak Performance on Instagram

Dr. Ganesh Anand is an Associate Professor of Chemistry as well as Biochemistry and Molecular Biology at The Pennsylvania State University (or Penn State University) at the University Park campus. He is also an elected Board Member of the International Society for Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS). Research in Ganesh's lab examines molecular switches. He wants to know how molecules interact with one another and how they switch from one state to another. These tiny molecular switches act almost like electrical switches turning on and off the functions of different molecules. He also does research on viruses and how they change shape to infect their hosts. Beyond his scientific interests, Ganesh has also been passionate about music for as long as he can remember. He takes voice lessons now and enjoys singing in choirs in his free time. He received his bachelor's degree in pharmacy and his master's degree in biological sciences from Birla Institute of Technology and Science in India. Next, Ganesh attended Rutgers University where he earned his PhD in biochemistry. Afterwards, he conducted postdoctoral research as a Howard Hughes Medical Institute Research Fellow at the University of California San Diego. Ganesh served on the faculty in the Department of Biological Sciences at the National University of Singapore for over a decade before accepting a faculty position at Penn State where he is today. His lab is recognized as a Waters World Center of Innovation in Hydrogen/Deuterium Exchange Mass Spectrometry. Ganesh is founding member and former Director of the Singapore National Laboratory for Mass Spectrometry (SingMass) and the former Vice President of the Singapore Society for Mass Spectrometry. In this interview, he shares more about his life and science.

In today's OncClub episode, we had the pleasure of speaking with Branden Moriarity, PhD; and Beau Webber, PhD, about a study evaluating neoantigen-reactive CISH knockout tumor-infiltrating lymphocyte (TIL) therapy in patients with metastatic gastrointestinal cancers. Dr Moriarity is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the Center for Genome Engineering and the Genome Engineering Shared Resource (GESR), and a member of the Center for Genome Engineering at the University of Minnesota in Minneapolis, where he is also a faculty member in the Department of Pediatrics; the Microbiology, Immunology and Cancer Biology (MICaB) PhD Graduate Program; the PhD Program in Molecular, Cellular, Developmental Biology and Genetics; the Cellular and Molecular Biology (CMB) Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Stem Cell Institute at the Masonic Cancer Center. Dr Webber is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the GESR, and a member of the Stem Cell Institute at the University of Minnesota Medical School, where he is also a faculty member in the Department of Pediatrics, the Molecular Pharmacology & Therapeutics Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Masonic Cancer Center. In our exclusive interview, Drs Moriarity and Webber discussed how targeting the CISH gene using CRISPR enhances T-cell function, key safety and efficacy findings from this study in 12 patients, and future research efforts that may focus on reducing manufacturing time and cost, as well as enhancing T-cell resilience. Check out the full OncClub subseries to see additional findings and insights from this research!

At the 2025 Kidney Cancer Research Summit hosted by KidneyCAN, CancerNetwork® spoke with a variety of leading experts about key developments in the research and management of kidney cancer. Throughout the meeting, presenters shared their findings related to updated clinical trial results, personalized cancer vaccines, potential biomarkers of interest, and other advancements in the field. Thomas Powles, MBBS, MCRP, MD, discussed outcomes from a quality-adjusted survival time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITESPARK-005 trial (NCT04195750), in which investigators evaluated treatment with belzutifan (Welireg) vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC). Powles, a professor of genitourinary oncology, lead for Solid Tumor Research, and director of Barts Cancer Institute at St. Bartholomew's Hospital, Queen Mary University of London, stated that these data demonstrate how belzutifan is more active and better tolerated than everolimus in this patient population. David A. Braun, MD, PhD, assistant professor at Yale School of Medicine and member of the Center of Molecular and Cellular Oncology within the Yale Cancer Center, detailed his presentation on a personalized neoantigen cancer vaccine as a treatment for those with RCC. Based on his presentation, Braun highlighted how neoantigen vaccines may effectively yield T-cell responses in patients, illustrating a need for additional, larger studies to elucidate the clinical activity of this modality in an adjuvant setting. Additionally, Wenxin (Vincent) Xu, MD, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, spoke about his presentation on how kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker of response to therapy in patients with RCC. His research posed questions on how KIM-1 can inform the use of adjuvant therapy or specific therapeutic combinations like nivolumab (Opdivo) plus ipilimumab (Yervoy) for this patient population. Eric Jonasch, MD, gave an overview of his presentation focused on the Kidney Cancer Research Consortium, a research partnership spanning 7 institutions dedicated to facilitating mechanistic, hypothesis-testing clinical trials in RCC. Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, described how this collaboration aims to link identifiable biological characteristics of RCC subtypes to specific treatment strategies while developing predictive biomarkers. KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. You can learn more about KidneyCAN's work here: https://kidneycan.org/ References 1. Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. Abstract 13. 2. Braun DA. Personalized vaccines in kidney cancer: a journey from concept to clinic. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 3. Xu W. From bench to bedside: advancing KIM-1 as a tool for clinical decision-making. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 4. Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

Dr. Eric Balcavage interviews Nagina Abdullah about why traditional weight loss approaches fail for women with thyroid issues, especially in midlife. Nagina shares her personal journey from yo-yo dieting to losing 40 pounds using metabolism-focused strategies and reveals the framework she's used to help 1600+ women.   Key Topics Covered: Why "calories in, calories out" doesn't work in midlife How perimenopause changes metabolism and increases inflammation  The role of stress, sleep, and under-eating in weight gain  Nagina's "Tested & Perfected Fat Burning Food Framework"  Specific macro ratios: 40% protein, 35% healthy fats, 25% healthy carbs  When to use advanced strategies like "feeding up" and intermittent fasting  Why thyroid patients need digestive support and adequate carbohydrates The connection between liver function and T4 to T3 conversion Perfect for: Women over 40 struggling with weight despite "doing everything right," especially those with thyroid conditions seeking practical, science-based nutrition strategies.   Nagina Abdullah is the founder of MasalaBody. She is the metabolism expert for midlife women who feel like their bodies have turned against them. When nothing else works, she helps them fire up their metabolism, burn stubborn fat, and finally see results. After maintaining a 40-pound weight loss for over a decade, she used her Bloat Busting Protocol to shed 14 pounds of perimenopause weight. With a degree in Molecular and Cell Biology from UC Berkeley & an MBA from NYU, she blends scientific research with practical strategies to help midlife women boost their metabolism, shed stubborn weight, and create a sustainable, healthy lifestyle. While most midlife women are told to "eat less and exercise more," Nagina does the opposite. She replaces restriction with metabolism-boosting foods that melt belly fat & make healthy living effortless. Her proven methods have helped 1,600+ women finally break free from stubborn midlife weight, without frustration or deprivation.   Guest Links & Resources: 

In today's episode, we explore the groundbreaking intersection of addiction, biology, and cancer with internationally recognized scientist Dr. Rafael Cuomo. Drawing on insights from his book Crave, Dr. Cuomo reveals how addiction is not simply a behavioral or psychological issue—it's a biological condition that reshapes the terrain of our health and directly contributes to the development of chronic disease, including cancer. Dr. Cuomo introduces the concept of “molecular scars”—long-term physiological changes left behind by repeated addictive behaviors, even low-grade ones like screen use or ultra-processed food consumption. He explains how these behaviors disrupt key systems in the body, including the dopamine, opioid, GABA, glutamate, cortisol, and the endocannabinoid systems, ultimately weakening immune surveillance, fueling inflammation, and accelerating cellular damage. From the anticipatory nature of craving to the role of trauma and adverse childhood experiences, this episode invites clinicians, patients, and everyday listeners to reconsider addiction not as a character flaw, but as a biologically driven imbalance with profound public health implications.

Before adjusting your thyroid meds, have you ever ruled out gut-based triggers?Gut imbalances can have a bigger impact on thyroid health than most realize, especially in autoimmune conditions like Graves' and Hashimoto's. When the gut barrier breaks down, the immune system can get confused and prevent symptoms from fully improving. Testing can also be tricky, and just because something shows up doesn't always mean it needs to be treated. In this episode, I walk through how I approach these situations; how to evaluate critically, when to dig deeper, and when the priority should be foundational support like stress, sleep, and diet.Tune in to get a clearer picture of how gut health could be influencing your thyroid!Episode Timeline: 00:00 – Introduction to the Question00:08 – How infections can impact gut and thyroid function01:15 – Molecular mimicry and immune confusion01:35 – Infections and overgrowths that may influence autoimmunity02:36 – Testing methods and treatment preferences03:39 – Parasite treatment debates and false negatives05:07 – Why root cause work goes beyond infection treatment06:03 – Episode Wrap up06:40 – Podcast OutroFree resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Access hundreds of free articles at www.NaturalEndocrineSolutions.com Visit Dr. Eric's YouTube channel at www.youtube.com/c/NaturalThyroidDoctor/ To work with Dr. Eric, visit https://savemythyroid.com/work-with-dr-eric/

Are you a woman leader or entrepreneur considering a career pivot, especially from academia to the dynamic startup world? Do you wonder how to navigate this transition, build crucial relationships, and drive innovation in a new industry? This episode of How Women Inspire addresses these very challenges, offering invaluable insights into making a successful leap and fostering meaningful connections.This week's episode 177 of How Women Inspire Podcast is about transitioning from academia to startups! In this episode of How Women Inspire Podcast, Grace Wei is sharing the importance of building relationships and maintaining connections with experts and mentors. and actionable steps you can take right now to build a team culture at your startup. Grace Wei has held the position of COO at Encellin since 2016. Prior to that, Grace worked as a biologist at UCSF from 2005 to 2015. Grace Wei has a Bachelor's Degree in Human Genetics from McGill University and a Ph.D. in Molecular and Cellular Biology from the University of Chicago. Grace also completed programs at Stanford University Graduate School of Business and Y Combinator.Some of the talking points Julie and Grace go over in this episode include:Why building and maintaining strong relationships is paramount for founders and leadersThe unique benefits of different accelerators and how they can provide access to experts, community, and professional coaching for your startup journey.How transitioning from a specialized field like academia to a startup environment requires humility and a willingness to seek adviceThe importance of team culture for startup success, and how that differs from academia.What steps will you take today to cultivate your network and embrace new challenges?Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me!  And don't forget to follow, rate, and review the podcast and tell me your key takeaways!Learn more about How Women Inspire at https://www.howwomenlead.com/podcast CONNECT WITH GRACE WEI:LinkedInEncellinCONNECT WITH JULIE CASTRO ABRAMS:LinkedIn - JulieHow Women LeadHow Women InvestHow Women GiveInstagram - HWLLinkedIn - HWLFacebook - HWL

Two Women Inspiring Real Life with Stephanie Coxon and Kathy Anderson-Martin – Leaked memos suggest some want Robert F. Kennedy Jr. out as Secretary of Health & Human Services. Molecular biologist Dr. James Lyons-Weiler joins us to discuss who's behind this and why. We explore the trillion-dollar vaccine industry, informed consent, and the importance of critical thinking for your family's health...

Welcome back to today's Friday Review where I'll be breaking down the best of the week!     I'll be sharing specifics on these topics:     The Well-Lived Life (book review) Your First Lab Program (product review) “Molecular Jackhammers” & Cancer (research)     For all the details tune in to today's Cabral Concept 3444 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3444 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  WFNMB and the AOCNMB meetingsIn this podcast, we talk about the upcoming meetings of the World Federation of Nuclear Medicine and Biology and the Asia Oceania Congress of Nuclear Medicine and Biology  https://www.wfnmb.org/https://aocnmb2025.com/TAGS WFNMB,AOCNMB,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

Dr. Michelle Starz-Gaiano is Professor and Chair of Biological Sciences at the University of Maryland Baltimore County (UMBC). Michelle's research uses fruit flies to examine how cells in the body go to the right place at the right time. Understanding why and how cells use their genetic information to move through the body is critical because if this movement doesn't happen correctly, it could, for example, impact embryo development or affect how immune cells mobilize after an injury. Conversely, preventing cancer cells from moving could keep cancer from spreading to other parts of the body. Michelle often spends her free time cooking and baking. Her kitchen looks a little like a lab, and she enjoys experimenting with making different foods. Michelle and her family also like to spend time together, travel, and listen to music. She received her bachelor's degree in biology from the Massachusetts Institute of Technology and her PhD in Developmental Genetics from New York University. Afterwards, Michelle completed a postdoctoral fellowship at Johns Hopkins School of Medicine. She joined UMBC in 2008 and has received the Donald Creighton Outstanding Faculty Member Award from the UMBC Graduate Student Association for her excellent mentorship. In our interview, she shares more about her life and science.

About Nagina Abdullah: Nagina Abdullah is a weight-loss coach for women in midlife and founder of the top-rated website MasalaBody.com. Nagina has a degree in Molecular and Cell Biology from UC Berkeley and earned an MBA at NYU. She has helped more than 1,500 women in midlife successfully lose weight permanently and create a lifestyle change. Nagina teaches women to boost their metabolism naturally to burn fat even when nothing else has worked. She focuses on adding and combining natural metabolism-boosting foods to reduce belly fat and get women unstuck so that they can live in their dream body.   What We Discuss In This Episode: The "Add, Don't Subtract" Method: How Eating More Helps Midlife Women Lose More Weight How to Debloat, Reduce Inflammation, & Burn Fat Naturally (Even After Menopause) How to Get Off Sugar with the 4-Part Fat-Burning Food Framework (While Still Enjoying Chocolate Cake!) How to Boost Metabolism to Lose Weight (Without Calorie Counting or Dieting) How to Boost Your Metabolism in Midlife by Adding, Timing, and Pairing Foods   Free Resource From Nagina Abdullah: Sweet Spice Cheat Sheet, which reveals the spice in your kitchen that helps curb sugar cravings and lower blood sugar—naturally. It includes: 3 powerful health benefits of this spice 5 simple ways to use it daily 1 easy recipe to get started

BUFFALO, NY – June 27, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.” In this study, researchers led by first authors Cleto Dantas Nogueira from the Federal University of Ceará and Argos Pathology Laboratory and Samuel Frota from Argos Pathology Laboratory, along with corresponding author Fabio Tavora from the previously mentioned institutions and Messejana Heart and Lung Hospital, investigated how HER2 gene mutations appear in cases of non-small cell lung cancer (NSCLC) in Northeastern Brazil. The team found that HER2 mutations showed significant genetic diversity and were often associated with other cancer-related genetic changes. These findings revealed diagnostic and treatment challenges in a population that is rarely studied, emphasizing the need for expanded access to molecular testing and targeted therapies. HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer—particularly NSCLC—these mutations are less common but remain clinically significant. Most existing research on HER2-mutated lung cancer focuses on high-income countries, leaving important gaps in knowledge about underrepresented regions such as Latin America. This study helps fill that gap by analyzing 13 patients with HER2-mutated NSCLC using clinical, pathological, and genomic data. The patients ranged in age from 34 to 82 years, and more than half were women. About half had never smoked. Their tumors often displayed complex genetic profiles, including additional mutations in genes such as TP53, KRAS, and STK11. The most common HER2 mutation identified was an insertion in exon 20, a known hotspot for activating mutations. “Trastuzumab deruxtecan (T-DXd) is the first HER2-targeted agent to show clinical efficacy in HER2-mutant non-small cell lung cancer (HER2m NSCLC).” Treatment strategies among the patients varied. Only one individual received HER2-targeted therapy. Most were treated with surgery, chemotherapy, immunotherapy, or a combination of these approaches. Outcomes also differed, with some patients surviving for years and others dying within months of diagnosis. These findings reinforce the need for early diagnosis and improved access to advanced treatments, particularly in low-resource settings. The study emphasizes the value of comprehensive molecular profiling in NSCLC. Because HER2 mutations often occur alongside other genetic alterations, full genomic analysis is crucial for guiding treatment decisions. Yet, such testing is not always available. The researchers propose a tiered diagnostic approach, beginning with basic screening and expanding to more advanced tests when necessary, to enhance patient care. This study provides valuable insights into the molecular characteristics of HER2-mutated NSCLC in a Brazilian population, highlighting the complexity and clinical relevance of these alterations. Larger studies are needed to clarify the prevalence and prognostic significance of HER2 mutations, as well as their impact on treatment response and survival. This knowledge is essential for advancing effective HER2-targeted therapies. The findings also support broader implementation of international clinical guidelines in Latin America and highlight the critical need to include underrepresented populations in cancer research. DOI - https://doi.org/10.18632/oncotarget.28737 Correspondence to - Fabio Tavora - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=hr5R9iDBFFI To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Why is the universe the way it is? Wherever we look, we find ordered structures: from stars to planets to living cells. Molecular Storms: The Physics of Stars, Cells and the Origin of Life (Springer Nature, 2023) shows that the same driving force is behind structure everywhere: the incessant random motion of the components of matter. Physicists call it thermal noise. Let's call it the molecular storm. This storm drives the fusion reactions that make stars shine. It drives whirlpools and currents in atmospheres and oceans. It spins and distorts molecules until they are in the right orientation to react and form new substances. In living cells, it drives proteins to fold and molecules to self-assemble. It is behind every detail of the astonishing molecular machines that control cellular processes. Using cutting-edge research, "Molecular Storms" takes us on a dazzling journey from the early universe to the interior of the smallest living things. There, in a nanoscale world of biological devices, it explains the physics behind the chemical system which we call Life. Whether you're someone with a general interest in science or a student looking to add context to your studies, this book is for you. "Molecular Storms" is an accessible and captivating read that will deepen your appreciation of the power of science to explain the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Seth Diehl, our newest Ortho rep, joins me today to walk us through what makes the Ortho Molecular products exceptionally high quality and why they are our top choice. He explains how Ortho Molecular Products is the only remaining practitioner and supplement manufacturer and the only company that has not sold out. We also dive into our latest products, Choline Support, L-Theanine, Inositol Complex, Estro Support, Milk Thistle, and Neuro Support Magnesium. The benefits of combining L-Theanine with your morning coffee: It reduces the jittery caffeine excitement  It provides a relaxed energy boost It supports GABA, the most calming neurotransmitter Seth Diehl's Bio: Seth Diehl is an Account Executive with Ortho Molecular Products, proudly supporting healthcare practitioners throughout Iowa, including myself and the exceptional team at Integrative Health and Hormone Clinic.  Seth earned both his Bachelor's in Biology and Master's in Biomedical Sciences from Iowa State University. Initially unfamiliar with integrative and functional medicine, Seth quickly became an enthusiastic advocate after discovering the impactful role preventative approaches play in overall health.  Today, he combines his scientific expertise with a genuine passion for wellness, providing healthcare professionals with tailored health solutions and proactive patient care strategies. Seth feels privileged to collaborate with practitioners across his home state, backed by an organization that supports the transformation of the practice of medicine alongside integrative and functional medicine providers nationwide. In this episode: What differentiates Ortho Molecular Products from the rest, making them the best supplement manufacturer? How they use trademarked and patented raw materials throughout their product lines to ensure therapeutic outcomes Why you need to be careful when following the advice of influencers on social media- especially those with no background in healthcare  How Ortho Molecular Products safeguards its manufacturing processes by adhering to FDA regulations for its food and pharmaceutical products  How Choline Support supports cellular and mitochondrial membranes for better brain health and more energy How L-Theanine reduces stress and promotes relaxation without causing drowsiness How the unique form of magnesium in Neuro Magnesium Support improves sleep quality and memory and reduces brain fog How our new product, Inositol Complex, can be used to address the symptoms of PCOS How Estro Support helps women manage their menopause symptoms How Milk Thistle aids liver detoxification Links and Resources: Use code ENERGY to get 10% off ⁠⁠MITOCHONDRIAL COMPLEX Use code TURMERIC to get 10% off ⁠⁠TURMERIC Try Halo (Salt) Therapy for respiratory and skin health. Call 319-363-0033 to schedule your session. Relative Links for This Show: Neuro Magnesium Support  L-Theanine – 60 capsules Use code PODCAST for 10% off your next supplement purchase  Inositol Complex Choline Support EstroSupport Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

Stephen Wolfram answers questions from his viewers about the future of science and technology as part of an unscripted livestream series, also available on YouTube here: https://wolfr.am/youtube-sw-qaTopics discussed: The limits and future of software defined everything - Molecular design and biological engineering - Human enhancement and genome level modification

The creation of a landmark gene editing drug used to treat a baby with a rare genetic mutation which could help transform personalized medicine. Blood tests showed baby KJ had sky-high levels of ammonia, a toxic substance the body usually expels. The root cause was his genes - or more particularly a specific gene mutation. The race was on to try and treat him before his condition took a firm hold. His doctors came up with a radical solution - for the first time ever, they designed and applied a gene-editing drug in record time, specifically for him. Have we seen breakthrough in preventing genetic diseases? With Fyodor Urnov, a professor in the Molecular and Cell Biology Department at the University of California, Virginijus Šikšnys professor at the Life Science Center of Vilnius University, Waseem Qasim from the UCL Institute of Child Health in Great Ormond Street Hospital in London and Jennifer Doudna, Professor, University of California, Berkeley and founder of the Innovative Genomics Institute. Presented by Tanya Beckett. Produced by Bob Howard. Researched by Mauve Schaffer Edited by Tara McDermott.

Feel like your body's no longer responding the way it used to—despite doing everything “right”? In this episode, we're diving into the world of bioactive peptides: what they are, how they work, and why they're becoming a game changer for women over 35 dealing with fatigue, muscle loss, inflammation, and hormone shifts. We break down the science behind Make Wellness peptides and how they help your body heal, rebuild, and thrive from the inside out.   Hosted by Leanne Vogel.   Coaching and other supports available at: https://shop.healthfulpursuit.com/    Podcast Sponsors, links and offers available at: https://www.healthfulpursuit.com/podcast/  Bioactive Peptides: https://www.healthfulpursuit.com/make 

Garrett Butler, MD. Husband, father, son, friend, and family doc in rural WV. Undergraduate in Physics from Johns Hopkins University. Undergraduate in Molecular and Cell Biology from Towson University. MD from West Virginia University School of Medicine. Family Medicine residency at WVU SOM. Hospitalist at Vandalia Health Davis Medical Center. Outpatient family physician at Vandalia Health Broaddus Family Care. Hospitalist at Vandalia Health Broaddus Hospital. Medical director of Mansfield Place nursing home. Work With Us: Arétē by RAPID Health Optimization Links: Dr. Garrett Butler - Old Fellow Manor Anders Varner on Instagram Doug Larson on Instagram Coach Travis Mash on Instagram